Chronic Kidney Disease Clinical Trials

Find Chronic Kidney Disease Clinical Trials Near You

Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis: A Prospective Observation Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Patients with end-stage renal disease (ESRD) often require arteriovenous grafts (AVG) for hemodialysis. AVG thrombosis is a common complication, usually managed by percutaneous transluminal angioplasty (PTA) to restore blood flow. PTA achieves patency by balloon-mediated compression and fragmentation of thrombus. Small thrombus fragments may enter the venous circulation and cause transient pulmonary microembolism, leading to ventilation-perfusion (V/Q) mismatch. This study uses electrical impedance tomography (EIT) to noninvasively monitor short-term changes in regional ventilation and perfusion during and after PTA, exploring the immediate pulmonary physiological consequences of thrombus fragmentation and revascularization in dialysis patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years.

• Diagnosis of end-stage renal disease receiving maintenance hemodialysis.

• Documented AVG thrombosis requiring PTA.

• Able to cooperate and tolerate EIT monitoring.

• Provided written informed consent.

Locations
Other Locations
China
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)
RECRUITING
Wuhu
Contact Information
Primary
qiancheng xu, PhD
qianchengxu@wnmc.edu.cn
+86-18297529106
Time Frame
Start Date: 2024-10-24
Estimated Completion Date: 2027-12-30
Participants
Target number of participants: 20
Treatments
Observation Cohort
All enrolled patients will undergo clinically indicated PTA under standard care. EIT monitoring will be performed continuously before, during, and after recanalization to record regional ventilation and perfusion data. No experimental drug or device will be administered beyond routine care.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Wannan Medical College

This content was sourced from clinicaltrials.gov